PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ajbrLink to Publisher's site
 
Am J Blood Res. 2012; 2(1): 9–17.
Published online Jan 1, 2012.
PMCID: PMC3301435
Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis
Vaishali Sanchorawala
Amyloid Treatment and Research Program and Stem Cell Transplantation Program of Section of Hematology and Oncology, Boston Medical Center, Boston, MA 02118, USA
Address correspondence to: Dr. Vaishali Sanchorawala, Amyloid Treatment and Research Program and Stem Cell Transplantation Program of Section of Hematology and Oncology, Boston Medical Center, Boston, MA 02118, USA. E-mail: vaishali.sanchorawala/at/bmc.org
Received December 18, 2011; Accepted December 30, 2011.
Abstract
AL amyloidosis is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. The disease is often difficult to recognize because of its broad range of manifestations and, what are often, vague symptoms. Recent diagnostic and prognostic advances include the serum free light chain assay, cardiac magnetic resonance imaging, and serologic cardiac biomarkers. Treatment strategies that have evolved during the past decade are prolonging survival and preserving organ function in patients with this disease. This review outlines the role of high dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.
Keywords: AL amyloidosis, stem cell transplantation, melphalan
The amyloidoses are a group of diseases that share a common feature of extracellular deposition of pathologic, insoluble, fibrils in many tissues and organs. These fibrils have a characteristic beta-pleated sheet configuration that stains with the Congo red dye, producing apple green birefringence under polarized light microscopy [1]. Classification of the amyloidoses is based upon the precursor protein that forms the amyloid fibrils, and the distribution of amyloid deposition (systemic or localized) [2].
Immunoglobulin light-chain (AL) amyloidosis is the most common form of systemic amyloidosis in the US and Europe. Although AL amyloidosis is considered an uncommon disease, it has an incidence similar to Hodgkin lymphoma or chronic myelogenous leukemia [3]. It affects 5 to 12 persons/million/year, although autopsy studies suggest that the actual incidence might be higher. The annual incidence of AL amyloidosis in Olmstead County, Minnesota, is 8 in a million patients [4]. The amyloiodogenic precursor protein in AL amyloidosis is an immunoglobulin light chain or a fragment of light chain, usually the variable region, produced by the clonal plasma cell population in the bone marrow. The plasma cell burden in this disorder is usually low (5-10%), although AL amyloidosis can be associated with multiple myeloma in 10- 15% of cases [5].
A detailed elaboration of the pathogenesis of AL amyloidosis is beyond the scope of this paper. However, each of the steps in the pathogenesis of amyloidosis, from the production of the precursor protein to formation of amyloid deposits, is a potential target for treatment [6]. Preclinical and clinical studies are being designed or are ongoing for several of these targets. Reducing the amyloidogenic precursor protein, i.e. light chains produced by the clonal plasma cell dyscrasia, with chemotherapeutic agents has been used for the past several decades. Several interventions aimed at facilitating degradation of the amyloid deposits have been reported in AL amyloidosis. A detailed description of all the treatment options is beyond the scope of this paper.
The two keys to effective treatment of AL amyloidosis are early diagnosis and correct typing. Ideally, treatment should be started before irreversible organ damage has occurred. Once the diagnosis of AL has been firmly established, the design of the therapeutic strategy depends on a fine balance between the efficacy of the chosen regimen and the individual patient's expected ability to tolerate the toxicity of the treatment regimen, especially in the setting of cardiac involvement with amyloidosis. The current therapeutic approach to systemic amyloidosis is based upon the observation that organ function restored if the synthesis of the amyloidogenic protein precursor is shut down. Therefore, the aim of therapy in AL amyloidosis is to rapidly reduce the supply of misfolded amyloid-forming monoclonal free light chains by suppressing the underlying plasma cell dyscrasia while using supportive measures to preserve target organ functions.
The criteria for hematologic and organ responses have been unified, formalized and recently updated at the XIIth International Symposium on Amyloidosis [7]. Hematologic response usually translates into clinically improved organ function and is associated with a substantial survival advantage and improved quality of life. However, if the organ damage is advanced, it may be irreversible despite hematologic remission. Most patients with a hematologic response show a clinical response after 3–6 months although late responses have been observed. While partial responses can be beneficial, it appears that significant reductions in free light chain levels are associated with the best clinical responses [8,9]. However, the rate of clinical response is higher in patients with a complete hematologic response than in those with a partial one.
High-dose intravenous melphalan chemotherapy and autologous peripheral blood stem cell transplantation has been successful in inducing complete hematologic remissions and prolonging survival in multiple myeloma [10,11]. Therefore, it was logical to apply this approach to the treatment of AL amyloidosis. The Amyloid Research and Treatment Program at Boston University School of Medicine has a long-standing investigative interest in the pathophysiology and treatment of the various forms of systemic amyloidoses. In 1994, a multidisciplinary clinical group was formed at Boston University Medical Center to develop high-dose chemotherapy protocols for AL amyloidosis. This group was made up of clinicians allied with the Amyloid Research and Treatment Program, representing the disciplines of cardiology, nephrology, pulmonology, neurology, gastroenterology and rheumatology, together with hematologists in the Stem Cell Transplant Program of the Section of Hematology and Oncology and clinical pathologists from the Aphersis and Blood Bank.
We reported our initial experience with high-dose melphalan and stem cell transplantation (HDM/SCT) in five patients with AL amyloidosis in 1996 [12]. This pilot study showed that AL amyloidosis patients with significant systemic disease could be successfully treated with HDM/SCT. Furthermore, three of the five patients achieved a complete hematologic response (CR), with disappearance of their underlying clonal plasma cell disorder following treatment. Moreover, all five patients experienced reversal of amyloid related organ dysfunction.
An expanded series of 312 patients was reported from our group in 2004 [13]. Hematologic complete responses occurred in 40% of evaluable patients and 66% of the patients achieved improvement in at least one organ function with a hematologic CR. Moreover, the median survival was 4.6 years for this cohort.
We reviewed the long-term follow up on 80 patients treated in the first 3 years of the program (1994-1997) [14]. The early death rate, within 100 days of SCT, was 14%. Hematologic CR was achieved by 51% (32/63) and the median survival was 4.75 years. The median survival exceeds 10 years for patients achieving a CR after HDM/SCT, compared with 50 months for those not achieving a CR. The long-term survival beyond 10 years was achieved in 23.5% (95% CI, 15% and 33%) of patients with AL amyloidosis treated with HDM/SCT. Hematologic relapses occurred in 34% (n =11/32) patients at a median time of 2.5 years (range, 2–8).
Recently, we have analyzed the outcome of 421 patients treated with HDM/SCT from July 1994 to December 2008 [15]. Treatment-related mortality was 11% overall, decreased to 6% in the last 5 years. For this group, the median event-free survival (EFS) and overall survival (OS) were 2.6 and 6.3 years, respectively. Of 340 patients evaluable at 1 year beyond HDM/SCT, 43% achieved CR and 78% of them experienced an organ response. For CR patients, median EFS and OS were 8.3 and 13.2 years, respectively. Among the 195 patients who did not obtain CR, 52% reached an organ response, and the median EFS and OS were 2 and 5.9 years, respectively. A subgroup of 26% of the non-CR patients remained clinically stable at 5 years of follow-up. Hematologic relapses occurred in 40 patients (28%) at a median time of 3.7 years (range, 1.5 to 12.7).
Our eligibility criteria for treatment with HDM/ SCT require a confirmed tissue diagnosis of amyloidosis, clear evidence of a clonal plasma cell dyscrasia, age >18 years, and minimum measures of performance status (SWOG 0–2), cardiac function (LVEF >40%), pulmonary function (O2 saturation >95% on room air), and hemodynamic stability (baseline systolic blood pressure >90 mm Hg). Patients on hemodialysis or peritoneal dialysis for renal failure are not excluded if other eligibility criteria are met [13]. The dose of melphalan can vary from 100-200 mg/m2 based on the risk-adapted approach, described by Comenzo and Gertz to reduce treatment-related morbidity and mortality associated with HDM/SCT [16]. The patients can be stratified into three risk categories as follows: (a) good risk patients are of any age and have 1 –2 organs involved, no cardiac involvement and creatinine clearance >50 mL/min, (b) intermediate risk patients are <71 years old and have 1– 2 organs involved, one of which must include cardiac or renal with creatinine clearance <51 mL/min, and (c) poor risk patients have either three organs involved or advanced cardiac involvement. Cardiac biomarker staging system can also define risk of treatment-related complications while undergoing HDM/SCT [17,18]. Elevated cardiac troponin T levels are associated with poor survival while undergoing HDM/ SCT [19].
Because the burden of clonal plasma cells is modest in most patients with AL amyloidosis, induction with a cytoreducing regimen prior to HDM/SCT, as is done in multiple myeloma, seems unnecessary although possible benefits from VAD treatment before SCT have been reported [20]. Evidence from a randomized clinical trial indicates that the delay associated with pretransplant cytoreduction, using oral melphalan and prednisone (MP), can allow disease progression and can lead to survival disadvantage in patients with cardiac involvement [21]. Induction therapy with novel agents prior to HDM/SCT, specifically bortezomib and dexamethasone, is being explored in the setting of a clinical trial and preliminary data of this appears promising.
Previous exposure to alkylating agents impairs hematopoietic stem cell collection. A total dose of oral melphalan exceeding 200 mg may significantly reduce the ability to mobilize CD34+ cells. Contrary to the common experience in multiple myeloma, deaths have been reported during mobilization and leukapheresis of patients with AL amyloidosis who have cardiac or multiorgan involvement [13]. Overall, the incidence of major complications, during stem cell mobilization and collection is approximately 15%. To minimize the risk of toxicity it is recommended that only granulocyte colony-stimulating factor (G-CSF) be used for mobilization, since its use in combination with cyclophosphamide is associated with increased cardiac morbidity, a significantly higher number of aphereses required for CD34 harvesting, greater need of hospitalization, and increased toxicity, although cyclophosphamide may have a role in stem cell mobilization in patients with AL amyloidosis and multiple myeloma. The recommended dose of G-CSF is 10-16 mcg/kg/day, either as a single dose or in two divided doses, 3 days prior to stem cell collection. The recommended optimal dose of CD34+ cells in AL patients is at least 5 x 106 CD34+ cells/kg [22]. Contamination of the apheresis product with clonotypic plasma cells has been demonstrated, but CD34 selection is not presently recommended [23]. Plerixafor, CXCR4 receptor antagonist, as a stem cell mobilization regimen has not been studied in patients with AL amyloidosis in a well-designed clinical trial [24].
Total body irradiation (550 cGy) prior to stem cell transplantation was investigated in a small feasibility study but is not used in current regimens because of cardiac toxicity and what appears to be greater overall morbidity and mortality. Thus, conditioning is usually performed with intravenous melphalan alone, using a risk-adapted dose modification schema. Tandem cycles of HDM have been shown to improve the proportion of patients who ultimately achieve a hematologic CR in 31% of patients, leading to overall CR rate of 67% [25]. A pilot study of incorporation of brotezomib with HDM in the treatment of AL amyloidosis has shown promising results with high hematologic response rates [26].
The initial report of renal responses following HDM/SCT was published in 2001. In this report, 36% of patients had a renal response at 12 months defined as a 50% reduction in 24 hour urinary protein excretion in the absence of a 25% or greater reduction in creatinine clearance [27]. There was a striking difference in renal response rate among those with a complete hematologic response (71%) and those with persistence of the plasma cell dyscrasia (11%). Since then, reports of improvements in quality of life [28], hepatic responses [29] and cardiac responses [30] have been published. Similar to renal response, clinical responses in other organ systems are more evident with hematologic responses and can take up to 6-12 months or longer to occur.
Patients with AL amyloidosis typically have organ impairment that predisposes them to increased peri-transplant morbidity and mortality. Unique clinical challenges with AL amyloidosis patients that warrant special mention relate to the management of nutrition, macroglossia, orthostatic hypotension, volume status and cardiac arrhythmias. Pre-transplant assessment of gastrointestinal function and mucosal integrity is essential. We have found that appropriate assessment includes a detailed review of gastrointestinal signs and symptoms, serial stool exams for occult blood loss, endoscopic studies to define pathology if indicated, and a complete assessment of coagulation status. Patients with poor nutrition because of gastrointestinal dysfunction and dysmotility, anorexia, or dysgeusia have generally required oral or parenteral nutrition supplements in the pre- and post-transplant period. Nephrotic syndrome associated with renal amyloidosis has been observed not uncommonly to lead to severe hypoalbuminemia and peripheral edema or anasarca. In patients with anasarca and serum albumin levels <2.0 g/dL, we have found that albumin infusions to raise the serum albumin followed by loop diuretics are effective. Hypoalbuminemia, autonomic insufficiency, hypoadrenalism, and cardiac disease can all lead to severe hypotension. Cardiac disease has been observed to predispose patients to atrial and ventricular arrhythmias as well as to symptoms and signs of restrictive cardiomyopathy [31]. Management of such patients in coordination with an experienced cardiologist has proven to be critical. Amiodarone is often an effective anti-arrhythmic, while beta blockers, calcium channel blockers, and digoxin have often been poorly tolerated by these patients. Deficiency of factor X, along with the poor endothelial and connective tissue integrity from amyloid deposition, is associated with an increased risk of cutaneous and mucosal bleeding, including pathognomonic “raccoon eye” periorbital ecchymoses. Patients with factor X deficiency are at particularly high risk of bleeding complications during periods of thrombocytopenia [32]. Hence, we have found that screening for factor X deficiency must be done prior to treatment. Neither fresh frozen plasma nor cryoprecipitate are abundant sources of factor X; significant bleeding due to factor X deficiency is best treated with factor IX complex or recombinant factor VIIa. Additional unusual problems that may be encountered in these patients include difficulties with emergent endotracheal intubation in patients with macroglossia, spontaneous splenic [33], esophageal and hepatic rupture [34], and hypercoagulability in association with nephrotic syndrome.
HDM/SCT is an effective treatment for AL amyloidosis. The results of single and multi-center studies are detailed in Table 1. Encouraging hematologic and clinical responses have been reported in these studies, though treatment-related mortality (TRM) is substantially higher (15-40%) than in multiple myeloma (<5%). A case-matched control study has suggested the superiority of HDM/SCT compared to conventional chemotherapy regimens [35], but the only randomized phase III study by the French group in the literature failed to show a survival benefit for HDM/SCT[36]. However, in this study, many of the patients randomized to the HDM/SCT arm were not actually transplanted, the toxicity on the transplant arm was excessive, and follow up is short. Thus, the question of optimal therapy remains open, particularly as transplant techniques are refined, and non-transplant regimens are improved. However, it is clear that patients should be carefully selected for transplant, as advanced cardiac disease, more than 2 organ involvement, hypotension and poor performance status are poor prognostic factors for the outcome of HDM/SCT.
Table 1
Table 1
Results of single and multi-center studies of HDM/SCT in AL amyloidosis
In patients with end-stage heart failure, heart transplantation may be required as a life-saving procedure. Because of the high likelihood of amyloid recurrence in the transplanted organ, as well as progression in other organs, heart transplantation must be followed by anti-plasma cell therapy. Although the long-term survival is statistically inferior to that of patients with non-amyloid heart disease, the actuarial 5-year survival appears to be 65% with treatment for the underlying plasma cell dyscrasia. Thus, carefully selected patients, without other significant organ involvement, can benefit from heart transplantation followed by aggressive anti-plasma cell treatment [37-39].
Supportive treatment aimed at improving or palliating organ function, maintaining quality of life, and prolonging survival while anti-plasma cell therapy has time to take effect has an important impact on survival. Supportive care should be considered a fundamental part of an integrated treatment approach to these patients and requires the coordinated expertise of several specialists who are familiar with this disease. Treatment of amyloid cardiomyopathy is highly specialized, as agents used for other cardiomyopathies can be dangerous in amyloidosis [40]. The mainstay of treatment is salt restriction and careful administration of diuretics, such as furosemide, scrupulously avoiding aggravation of intravascular volume contraction (due to concomitant nephrotic syndrome) and postural hypotension. If furosemide becomes ineffective in controlling edema, the addition of metolazone or spironolactone can be beneficial. Angiotensin-converting enzyme inhibitors should not be used routinely because of the high risk of precipitating hypotension in the setting of diastolic and autonomic dysfunction, but a few patients with reduced stroke volume can benefit from these agents used with great caution. Digoxin can be toxic because of binding to amyloid in the heart, but is occasionally useful in patients with atrial fibrillation and rapid ventricular response. Calcium channel blockers can aggravate congestive heart failure. Patients with recurrent syncope may require permanent pacemaker implantation. Patients with ventricular arrhythmias may benefit from treatment with amiodarone or the use of artificial implantable cardiac defibrillators, though this has not been rigorously proven. In patients with end-stage heart failure, heart transplantation is the only life-saving procedure, which may allow subsequent treatment to control the amyloidogenic clone. Orthostatic hypotension is challenging to manage. Midodrine can be helpful in some patients; urinary retention and piloerection are the main side effects, as supine hypertension is rare in these patients. The use of waist-high, fitted elastic stockings is helpful. In our experience fludrocortisone is poorly tolerated because of aggravation of fluid retention. Continuous noradrenalin infusion has been reported to be a successful treatment of severe hypotension refractory to conventional treatment. Therapy of renal amyloidosis is limited to the control of the edema by diuretics. The main damaging mechanism is progressive tubular injury caused by glomerular protein loss. The use of angiotensin-converting enzyme inhibitors, in an attempt to reduce proteinuria, is reasonable, although their efficacy has not been proven. Treatment of hyperlipidemia should be considered. Hypercoagulable state is rarely, if ever, seen in these nephrotic patients and prophylactic anticoagulation is not recommended. End-stage renal failure is treated by dialysis. Both peritoneal dialysis and hemodialysis are equally effective. If the disease is not controlled by chemotherapy, extrarenal progression of amyloidosis is the main cause of death. Renal transplantation should be offered on a case-by-case basis to patients without symptomatic extrarenal involvement [41]. Diarrhea is a common problem and can be incapacitating. Octreotide decreases diarrhea both in its short-acting form and its long-acting depository form. Chronic intestinal pseudoobstruction is usually refractory to treatment. Adequate oral or intravenous feeding is essential in patients with significant undernourishment. Patients who present with severe liver failure may be considered for liver transplantation; cases of successful sequential liver and stem cell transplantations have been reported [42]. Neuropathic pain is difficult to control. Gabapentin, although well-tolerated, often fails to relieve pain. Duloxetine may be effective in controlling pain of neuropathy. Non-nephrotoxic analgesics may be used as adjuvant agents. Bleeding in AL amyloidosis is frequent and multifactorial. Factor X deficiency can improve following effective chemotherapy, including HDM/ SCT [32], or after splenectomy.
Our data and that from other centers indicate that, despite multisystem organ dysfunction, selected patients with AL amyloidosis can tolerate high dose melphalan and autologous stem cell transplantation. Moreover, high-dose chemotherapy can induce complete hematologic responses in a substantial proportion of patients who complete treatment. Furthermore, complete hematologic responses in AL amyloidosis are associated with reversal of amyloid-related organ dysfunction and may lead to prolonged survival in this disease, which is typically fatal within 2 years when managed with standard oral chemotherapy regimens of oral cyclic melphalan and prednisone.
Over the past 17 years, we have treated a large number of AL amyloidosis patients with HDM/ SCT including patients over 65[43], patients on dialysis[44], and patients with early cardiac disease. While patient selection remains important in achieving an acceptable outcome, we also believe it is in part attributable to the multidisciplinary approach to patient management. A team of subspecialists who are familiar with the manifestations and treatment of amyloidosis, in our program, evaluate each patient. These subspecialists remain available to the transplant physicians throughout therapy, and the amyloid clinical team meets regularly to review each patient's progress during treatment. We encourage other transplant centers undertaking treatment of these complicated patients to adopt a similar multidisciplinary management approach.
Promising treatments, besides HDM/SCT, are available for patients with AL amyloidosis. Although these treatment regimens are not discussed here in this review, the availability of new regimens for treatment of AL amyloidosis may provide additional options for patients, who are not eligible for HDM/SCT in the future. Timing and sequencing of regimens containing these agents, and comparison to or combination with HDM/SCT, will be determined in future trials.
Prompt diagnosis of amyloidosis and appropriate referral has great potential to improve outcome for these patients. AL amyloidosis should be considered in the differential diagnosis of patients being evaluated for a variety of syndromes including nephrotic range proteinuria, unexplained non-ischemic cardiomyopathy, nondiabetic peripheral or autonomic neuropathy, and unexplained hepatomegaly. It is essential to recognize AL amyloidosis as the cause of macroglossia and periorbital ecchymoses. All patients presenting with monoclonal gammopathy or “smoldering” myeloma should be screened for nephropathy and cardiomyopathy on presentation and periodically afterwards. Despite improvements in the diagnosis and treatment of AL amyloidosis, continued basic and clinical research in this field is needed to continue to improve the outcome for these patients.
Acknowledgements
We gratefully acknowledge our colleagues in the Clinical Trials Office, and the staff of the Solomont Center for Cancer and Blood Disorders at Boston Medical Center who assisted with the multidisciplinary evaluation and treatment of the patients.
Disclosure of conflicts of interest
The author declares no competing financial interests.
1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583–596. [PubMed]
2. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid. 17:101–104. [PubMed]
3. Gertz MA LM, Dispenzieri A. Amyloidosis. Hematol Oncol Clin North America. 1999;13:1211–1220. [PubMed]
4. Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O'Fallon WM, Kurland LT. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79:1817–1822. [PubMed]
5. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45–59. [PubMed]
6. Dember LM. Emerging treatment approaches for the systemic amyloidoses. Kidney Int. 2005;68:1377–1390. [PubMed]
7. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79:319–328. [PubMed]
8. Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant. 2005;36:597–600. [PubMed]
9. Lachmann HJ, Gallimore R, Gillmore JD, Carr- Smith HD, Bradwell AR, Pepys MB, Hawkins PN. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122:78–84. [PubMed]
10. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91–97. [PubMed]
11. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–1883. [PubMed]
12. Comenzo RL, Vosburgh E, Simms RW, Bergethon P, Sarnacki D, Finn K, Dubrey S, Faller DV, Wright DG, Falk RH, Skinner M. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: oneyear follow-up in five patients. Blood. 1996;88:2801–2806. [PubMed]
13. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85–93. [PubMed]
14. Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. 2007;110:3561–3563. [PubMed]
15. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, Doros G, Blade J, Skinner M. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 118:4346–4352. [PubMed]
16. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99:4276–4282. [PubMed]
17. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J. Clin. Oncol. 2004;22:3751–3757. [PubMed]
18. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, Obici L, Ascari E, d'Eril GM, Moratti R, Merlini G. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107:2440–2445. [PubMed]
19. Gertz M, Lacy M, Dispenzieri A, Hayman S, Kumar S, Buadi F, Leung N, Litzow M. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma. 2008;49:36–41. [PubMed]
20. Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke RP, Ho AD, Goldschmidt H. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Br J Haematol. 2004;127:543–551. [PubMed]
21. Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM, Berk JL, Quillen K, Anderson JJ, Comenzo RL, Skinner M. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant. 2004;33:381–388. [PubMed]
22. Oran B, Malek K, Sanchorawala V, Wright DG, Quillen K, Finn KT, La Valley M, Skinner M. Seldin DC: Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant. 2005;35:567–575. [PubMed]
23. Comenzo RL, Michelle D, LeBlanc M, Wally J, Zhang Y, Kica G, Karandish S, Arkin CF, Wright DG, Skinner M, McMannis J. Mobilized CD34+ cells selected as autografts in patients with primary light-chain amyloidosis: rationale and application. Transfusion. 1998;38:60–69. [PubMed]
24. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Fruehauf S, Horwitz M, Cooper D, Bridger G, Calandra G. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720–5726. [PubMed]
25. Sanchorawala V, Wright DG, Quillen K, Finn KT, Dember LM, Berk JL, Doros G, Fisher C, Skinner M, Seldin DC. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplant. 2007 [PubMed]
26. Sanchorawala V, Quillen K, Sloan JM, Andrea NT, Seldin DC. Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Haematologica. 96:1890–1892. [PubMed]
27. Dember LM, Sanchorawala V, Seldin DC, Wright DG, LaValley M, Berk JL, Falk RH, Skinner M. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease. Ann Intern Med. 2001;134:746–753. [PubMed]
28. Seldin DC, Anderson JJ, Sanchorawala V, Malek K, Wright DG, Quillen K, Finn KT, Berk JL, Dember LM, Falk RH, Skinner M. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood. 2004;104:1888–1893. [PubMed]
29. Girnius S, Seldin DC, Skinner M, Finn KT, Quillen K, Doros G, Sanchorawala V. Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease. Haematologica. 2009;94:1029–1032. [PubMed]
30. Meier-Ewert HK, Sanchorawala V, Berk J, Finn KT, Skinner M, Seldin DC, Ruberg FL. Regression of cardiac wall thickness following chemotherapy and stem cell transplantation for light chain (AL) amyloidosis. Amyloid. 18(Suppl 1):125–126. [PubMed]
31. Meier-Ewert HK, Sanchorawala V, Berk JL, Ruberg FL. Cardiac amyloidosis: evolving approach to diagnosis and management. Curr Treat Options Cardiovasc Med. 13:528–542. [PubMed]
32. Choufani EB, Sanchorawala V, Ernst T, Quillen K, Skinner M, Wright DG, Seldin DC. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood. 2001;97:1885–1887. [PubMed]
33. Oran B, Wright DG, Seldin DC, McAneny D, Skinner M, Sanchorawala V. Spontaneous rupture of the spleen in AL amyloidosis. Am J Hematol. 2003;74:131–135. [PubMed]
34. Tam M, Seldin DC, Forbes BM, Connors LH, Skinner M, Oran B, Quillen K, Sanchorawala V. Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: a case report with literature review. Amyloid. 2009;16:103–107. [PMC free article] [PubMed]
35. Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Gertz MA. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 2004;103:3960–3963. [PubMed]
36. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, Asli B, Lioure B, Royer B, Jardin F, Bridoux F, Grosbois B, Jaubert J, Piette JC, Ronco P, Quet F, Cogne M, Fermand JP. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357:1083–1093. [PubMed]
37. Dey BR, Chung SS, Spitzer TR, Zheng H, Macgillivray TE, Seldin DC, McAfee S, Ballen K, Attar E, Wang T, Shin J, Newton-Cheh C, Moore S, Sanchorawala V, Skinner M, Madsen JC, Semigran MJ. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation. 90:905–911. [PMC free article] [PubMed]
38. Gillmore JD, Goodman HJ, Lachmann HJ, Offer M, Wechalekar AD, Joshi J, Pepys MB, Hawkins PN. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. In Blood. 2006:1227–1229. [PubMed]
39. Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Kyle RA, Rajkumar SV, Edwards BS, Rodeheffer RJ, Frantz RP, Kushwaha SS, Clavell AL, Dearani JA, Sundt TM, Daly RC, McGregor CG, Gastineau DA, Litzow MR, Gertz MA. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. J Heart Lung Transplant. 2008;27:823–829. [PubMed]
40. Seldin DC, Berk JL, Sam F, Sanchorawala V. Amyloidotic cardiomyopathy: multidisciplinary approach to diagnosis and treatment. Heart Fail Clin. 7:385–393. [PMC free article] [PubMed]
41. Sattianayagam PT, Gibbs SD, Pinney JH, Wechalekar AD, Lachmann HJ, Whelan CJ, Gilbertson JA, Hawkins PN, Gillmore JD. Solid organ transplantation in AL amyloidosis. Am J Transplant. 10:2124–2131. [PubMed]
42. Binotto G, Cillo U, Trentin L, Piazza F, Zaninotto M, Semenzato G, Adami F. Double autologous bone marrow transplantation and orthotopic liver transplantation in a patient with primary light chain (AL) amyloidosis. Amyloid. 18(Suppl 1):127–129. [PubMed]
43. Seldin DC, Anderson JJ, Skinner M, Malek K, Wright DG, Quillen K, Finn K, Oran B, Sanchorawala V. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood. 2006;108:3945–3947. [PubMed]
44. Casserly LF, Fadia A, Sanchorawala V, Seldin DC, Wright DG, Skinner M, Dember LM. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney Int. 2003;63:1051–1057. [PubMed]
45. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S. Transplantation for amyloidosis. Curr Opin Oncol. 2007;19:136–141. [PubMed]
46. Mollee PN, Wechalekar AD, Pereira DL, Franke N, Reece D, Chen C, Stewart AK. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplant. 2004;33:271–277. [PubMed]
47. Schonland SO, Perz JB, Hundemer M, Hegenbart U, Kristen AV, Hund E, Dengler TJ, Beimler J, Zeier M, Singer R, Linke RP, Ho AD, Goldschmidt H. Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis. Transplantation. 2005;80:S160–163. [PubMed]
48. Chow LQ, Bahlis N, Russell J, Chaudhry A, Morris D, Brown C, Stewart DA. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience. Bone Marrow Transplant. 2005;36:591–596. [PubMed]
49. Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, Hermine O, Attal M, Hamidou M, Nedellec G, Ferrant A, Audhuy B, Bataille R, Milpied N, Harousseau JL. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol. 1998;101:766–769. [PubMed]
50. Gertz MA, Blood E, Vesole DH, Abonour R, Lazarus HM, Greipp PR. A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study. Bone Marrow Transplant. 2004;34:149–154. [PubMed]
51. Goodman HJ, Gillmore JD, Lachmann HJ, Wechalekar AD, Bradwell AR, Hawkins PN. Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol. 2006;134:417–425. [PubMed]
52. Vesole DH, Perez WS, Akasheh M, Boudreau C, Reece DE, Bredeson CN. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study. Mayo Clin Proc. 2006;81:880–888. [PubMed]
Articles from American Journal of Blood Research are provided here courtesy of
e-Century Publishing Corporation